Fig. 3 From: The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European Medicines AgencyData summary: A Distribution of engagements for each drug, B Distribution of study types within engagements, and C Distribution of RCT and RWE studiesBack to article page